Randomized phase II study of the anti-inflammatory effect of ghrelin during the postoperative period of esophagectomy

Akihiro Takata, Shuji Takiguchi, Yasuhiro Miyazaki, Hiroshi Miyata, Tsuyoshi Takahashi, Yukinori Kurokawa, Makoto Yamasaki, Kiyokazu Nakajima, Masaki Mori, Kenji Kangawa, Yuichiro Doki

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Objective: A prospective randomized phase II trial was conducted to evaluate the efficacy of ghrelin administration in reducing systemic inflammatory response syndrome (SIRS) duration after esophagectomy. Background: Esophagectomy for esophageal cancer is highly invasive and leads to prolonged SIRS duration and postoperative complications. Ghrelin has multiple effects, including anti-inflammatory effects. Methods: Forty patients undergoing esophagectomy were randomly assigned to either the ghrelin group (n = 20), which received continuous infusion of ghrelin (0.5 μg/kg/h) for 5 days, or the placebo group (n = 20), which received pure saline for 5 days. The primary endpoint was SIRS duration. The secondary endpoints were the incidence of postoperative complications, time of a negative nitrogen balance, changes in body weight and composition, and levels of inflammatory markers, including C-reactive protein (CRP) and interleukin-6 (IL-6). Results: The ghrelin group had a shorter SIRS duration and lower CRP and IL-6 levels than did the placebo group. The incidence of pulmonary complications was lower in the ghrelin group than in the placebo group, whereas other complications did not differ between the groups. Although time of the negative nitrogen balance was shorter in the ghrelin group than in the placebo group, changes in total body weight and lean body weight did not differ significantly. Conclusions: Postoperative ghrelin administration was effective for inhibiting inflammatory mediators and improving the postoperative clinical course of patients with esophageal cancer.

Original languageEnglish
Pages (from-to)230-236
Number of pages7
JournalAnnals of surgery
Volume262
Issue number2
DOIs
Publication statusPublished - Aug 30 2015
Externally publishedYes

Fingerprint

Ghrelin
Esophagectomy
Postoperative Period
Anti-Inflammatory Agents
Systemic Inflammatory Response Syndrome
Placebos
Esophageal Neoplasms
C-Reactive Protein
Interleukin-6
Nitrogen
Body Weight
Incidence
Body Composition
Lung

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Takata, A., Takiguchi, S., Miyazaki, Y., Miyata, H., Takahashi, T., Kurokawa, Y., ... Doki, Y. (2015). Randomized phase II study of the anti-inflammatory effect of ghrelin during the postoperative period of esophagectomy. Annals of surgery, 262(2), 230-236. https://doi.org/10.1097/SLA.0000000000000986

Randomized phase II study of the anti-inflammatory effect of ghrelin during the postoperative period of esophagectomy. / Takata, Akihiro; Takiguchi, Shuji; Miyazaki, Yasuhiro; Miyata, Hiroshi; Takahashi, Tsuyoshi; Kurokawa, Yukinori; Yamasaki, Makoto; Nakajima, Kiyokazu; Mori, Masaki; Kangawa, Kenji; Doki, Yuichiro.

In: Annals of surgery, Vol. 262, No. 2, 30.08.2015, p. 230-236.

Research output: Contribution to journalArticle

Takata, A, Takiguchi, S, Miyazaki, Y, Miyata, H, Takahashi, T, Kurokawa, Y, Yamasaki, M, Nakajima, K, Mori, M, Kangawa, K & Doki, Y 2015, 'Randomized phase II study of the anti-inflammatory effect of ghrelin during the postoperative period of esophagectomy', Annals of surgery, vol. 262, no. 2, pp. 230-236. https://doi.org/10.1097/SLA.0000000000000986
Takata, Akihiro ; Takiguchi, Shuji ; Miyazaki, Yasuhiro ; Miyata, Hiroshi ; Takahashi, Tsuyoshi ; Kurokawa, Yukinori ; Yamasaki, Makoto ; Nakajima, Kiyokazu ; Mori, Masaki ; Kangawa, Kenji ; Doki, Yuichiro. / Randomized phase II study of the anti-inflammatory effect of ghrelin during the postoperative period of esophagectomy. In: Annals of surgery. 2015 ; Vol. 262, No. 2. pp. 230-236.
@article{34a2061c0d2947a69a38d9319c04d972,
title = "Randomized phase II study of the anti-inflammatory effect of ghrelin during the postoperative period of esophagectomy",
abstract = "Objective: A prospective randomized phase II trial was conducted to evaluate the efficacy of ghrelin administration in reducing systemic inflammatory response syndrome (SIRS) duration after esophagectomy. Background: Esophagectomy for esophageal cancer is highly invasive and leads to prolonged SIRS duration and postoperative complications. Ghrelin has multiple effects, including anti-inflammatory effects. Methods: Forty patients undergoing esophagectomy were randomly assigned to either the ghrelin group (n = 20), which received continuous infusion of ghrelin (0.5 μg/kg/h) for 5 days, or the placebo group (n = 20), which received pure saline for 5 days. The primary endpoint was SIRS duration. The secondary endpoints were the incidence of postoperative complications, time of a negative nitrogen balance, changes in body weight and composition, and levels of inflammatory markers, including C-reactive protein (CRP) and interleukin-6 (IL-6). Results: The ghrelin group had a shorter SIRS duration and lower CRP and IL-6 levels than did the placebo group. The incidence of pulmonary complications was lower in the ghrelin group than in the placebo group, whereas other complications did not differ between the groups. Although time of the negative nitrogen balance was shorter in the ghrelin group than in the placebo group, changes in total body weight and lean body weight did not differ significantly. Conclusions: Postoperative ghrelin administration was effective for inhibiting inflammatory mediators and improving the postoperative clinical course of patients with esophageal cancer.",
author = "Akihiro Takata and Shuji Takiguchi and Yasuhiro Miyazaki and Hiroshi Miyata and Tsuyoshi Takahashi and Yukinori Kurokawa and Makoto Yamasaki and Kiyokazu Nakajima and Masaki Mori and Kenji Kangawa and Yuichiro Doki",
year = "2015",
month = "8",
day = "30",
doi = "10.1097/SLA.0000000000000986",
language = "English",
volume = "262",
pages = "230--236",
journal = "Annals of Surgery",
issn = "0003-4932",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Randomized phase II study of the anti-inflammatory effect of ghrelin during the postoperative period of esophagectomy

AU - Takata, Akihiro

AU - Takiguchi, Shuji

AU - Miyazaki, Yasuhiro

AU - Miyata, Hiroshi

AU - Takahashi, Tsuyoshi

AU - Kurokawa, Yukinori

AU - Yamasaki, Makoto

AU - Nakajima, Kiyokazu

AU - Mori, Masaki

AU - Kangawa, Kenji

AU - Doki, Yuichiro

PY - 2015/8/30

Y1 - 2015/8/30

N2 - Objective: A prospective randomized phase II trial was conducted to evaluate the efficacy of ghrelin administration in reducing systemic inflammatory response syndrome (SIRS) duration after esophagectomy. Background: Esophagectomy for esophageal cancer is highly invasive and leads to prolonged SIRS duration and postoperative complications. Ghrelin has multiple effects, including anti-inflammatory effects. Methods: Forty patients undergoing esophagectomy were randomly assigned to either the ghrelin group (n = 20), which received continuous infusion of ghrelin (0.5 μg/kg/h) for 5 days, or the placebo group (n = 20), which received pure saline for 5 days. The primary endpoint was SIRS duration. The secondary endpoints were the incidence of postoperative complications, time of a negative nitrogen balance, changes in body weight and composition, and levels of inflammatory markers, including C-reactive protein (CRP) and interleukin-6 (IL-6). Results: The ghrelin group had a shorter SIRS duration and lower CRP and IL-6 levels than did the placebo group. The incidence of pulmonary complications was lower in the ghrelin group than in the placebo group, whereas other complications did not differ between the groups. Although time of the negative nitrogen balance was shorter in the ghrelin group than in the placebo group, changes in total body weight and lean body weight did not differ significantly. Conclusions: Postoperative ghrelin administration was effective for inhibiting inflammatory mediators and improving the postoperative clinical course of patients with esophageal cancer.

AB - Objective: A prospective randomized phase II trial was conducted to evaluate the efficacy of ghrelin administration in reducing systemic inflammatory response syndrome (SIRS) duration after esophagectomy. Background: Esophagectomy for esophageal cancer is highly invasive and leads to prolonged SIRS duration and postoperative complications. Ghrelin has multiple effects, including anti-inflammatory effects. Methods: Forty patients undergoing esophagectomy were randomly assigned to either the ghrelin group (n = 20), which received continuous infusion of ghrelin (0.5 μg/kg/h) for 5 days, or the placebo group (n = 20), which received pure saline for 5 days. The primary endpoint was SIRS duration. The secondary endpoints were the incidence of postoperative complications, time of a negative nitrogen balance, changes in body weight and composition, and levels of inflammatory markers, including C-reactive protein (CRP) and interleukin-6 (IL-6). Results: The ghrelin group had a shorter SIRS duration and lower CRP and IL-6 levels than did the placebo group. The incidence of pulmonary complications was lower in the ghrelin group than in the placebo group, whereas other complications did not differ between the groups. Although time of the negative nitrogen balance was shorter in the ghrelin group than in the placebo group, changes in total body weight and lean body weight did not differ significantly. Conclusions: Postoperative ghrelin administration was effective for inhibiting inflammatory mediators and improving the postoperative clinical course of patients with esophageal cancer.

UR - http://www.scopus.com/inward/record.url?scp=84938290876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938290876&partnerID=8YFLogxK

U2 - 10.1097/SLA.0000000000000986

DO - 10.1097/SLA.0000000000000986

M3 - Article

C2 - 25361222

AN - SCOPUS:84938290876

VL - 262

SP - 230

EP - 236

JO - Annals of Surgery

JF - Annals of Surgery

SN - 0003-4932

IS - 2

ER -